Literature DB >> 15384047

Allergen-induced traffic of bone marrow eosinophils, neutrophils and lymphocytes to airways.

Anna-Karin Johansson1, Svetlana Sergejeva, Margareta Sjöstrand, James J Lee, Jan Lötvall.   

Abstract

We evaluated whether bone marrow (BM) inflammatory cells have capacity to traffic into the airways following allergen exposure in a mouse model of allergen-induced airway inflammation. We also evaluated the effect of IL-5 overexpression on (i) the production of eosinophils in BM, (ii) the accumulation of eosinophils, neutrophils and lymphocytes in blood and airways and (iii) the changes in CD34+ cell numbers in BM, blood and airways. Bromodeoxyuridine (BrdU) was used to label cells produced during the exposure period. Furthermore, CD3 splenocytes were adoptively transferred to investigate the BM inflammatory response. Allergen exposure induced traffic of BM eosinophils, neutrophils and lymphocytes to the airways and increased the number of BrdU+ eosinophils, neutrophils, lymphocytes and CD34+ cells in BALf. IL-5 overexpression enhanced the eosinophilopoiesis and increased the presence of BrdU+ eosinophils and CD34+ cells in airways and enhanced the number of CD34+ cells in BM and blood after allergen exposure. Adoptive transfer of CD3 lymphocytes overexpressing IL-5 caused increased BM eosinophilia. In conclusion, allergen exposure induces traffic of not only newly produced eosinophils but also newly produced neutrophils and lymphocytes into the airways.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15384047     DOI: 10.1002/eji.200425043

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  8 in total

1.  Local proliferation and mobilization of CCR3(+)  CD34(+) eosinophil-lineage-committed cells in the lung.

Authors:  Madeleine Rådinger; Apostolos Bossios; Margareta Sjöstrand; You Lu; Carina Malmhäll; Anna-Karin Dahlborn; James J Lee; Jan Lötvall
Journal:  Immunology       Date:  2010-09-28       Impact factor: 7.397

2.  Bone marrow type 2 innate lymphoid cells: a local source of interleukin-5 in interleukin-33-driven eosinophilia.

Authors:  Kristina Johansson; Carina Malmhäll; Patricia Ramos-Ramírez; Madeleine Rådinger
Journal:  Immunology       Date:  2017-10-19       Impact factor: 7.397

3.  Rapamycin Dampens Inflammatory Properties of Bone Marrow ILC2s in IL-33-Induced Eosinophilic Airway Inflammation.

Authors:  Emma Boberg; Julie Weidner; Carina Malmhäll; Jenny Calvén; Carmen Corciulo; Madeleine Rådinger
Journal:  Front Immunol       Date:  2022-06-03       Impact factor: 8.786

4.  Expression of Toll-like receptor 9 in nose, peripheral blood and bone marrow during symptomatic allergic rhinitis.

Authors:  Mattias Fransson; Mikael Benson; Jonas S Erjefält; Lennart Jansson; Rolf Uddman; Sven Björnsson; Lars-Olaf Cardell; Mikael Adner
Journal:  Respir Res       Date:  2007-02-28

5.  Regulatory role of CD8+ T lymphocytes in bone marrow eosinophilopoiesis.

Authors:  Madeleine Rådinger; Svetlana Sergejeva; Anna-Karin Johansson; Carina Malmhäll; Apostolos Bossios; Margareta Sjöstrand; James J Lee; Jan Lötvall
Journal:  Respir Res       Date:  2006-06-01

6.  Airway allergen exposure stimulates bone marrow eosinophilia partly via IL-9.

Authors:  Brigita Sitkauskiene; Madeleine Rådinger; Apostolos Bossios; Anna-Karin Johansson; Raimundas Sakalauskas; Jan Lötvall
Journal:  Respir Res       Date:  2005-04-11

7.  Chronic, Elevated Maternal Corticosterone During Pregnancy in the Mouse Increases Allergic Airway Inflammation in Offspring.

Authors:  Arianna L Smith; Emmanuel Paul; Devin McGee; Ranuka Sinniah; Emily Flom; Devan Jackson-Humbles; Jack Harkema; Karen E Racicot
Journal:  Front Immunol       Date:  2020-01-21       Impact factor: 7.561

8.  Interleukin-25 and eosinophils progenitor cell mobilization in allergic asthma.

Authors:  Wei Tang; Steven G Smith; Wei Du; Akash Gugilla; Juan Du; John Paul Oliveria; Karen Howie; Brittany M Salter; Gail M Gauvreau; Paul M O'Byrne; Roma Sehmi
Journal:  Clin Transl Allergy       Date:  2018-02-13       Impact factor: 5.871

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.